Lung cancer perfusion at multi-detector row CT: Reproducibility of whole tumor quantitative measurements

Radiology

Volumn 239, Issue 2, 2006, Pages 547-553

  Ng, Quan Sing ^a   Goh, Vicky ^a   Fichte, Heinz ^b   Klotz, Ernst ^b   Fernie, Pat ^a   Saunders, Michele I ^a   Hoskin, Peter J ^a   Padhani, Anwar R ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b SIEMENS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IOBITRIDOL; XENETIX 300;

ADULT; AGED; APPARATUS; BLAND ALTMAN STATISTICS; BLOOD VOLUME; CLINICAL ARTICLE; COEFFICIENT OF VARIATION; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; LUNG CANCER; LUNG PERFUSION; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBSERVER VARIATION; PERMEABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; REVIEW; STATISTICAL ANALYSIS;

AGED; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY CIRCULATION; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33646136023     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2392050568     Document Type: Review

References (27)

1. Eskens FA. Angiogenesis inhibitors in clinical development: where are we now and where are we going? Br J Cancer 2004;90:1-7.
2. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
3. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM. Assessment of pharmacodynamic vascular response in a phase 1 trial of combretastatin A4 phosphate. J Clin Oncol 2003;21: 2823-2830.
4. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-2842.
5. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-4438.
6. Wintermark M, Maeder P, Verdun FR, et al. Using 80 kVp versus 120 kVp in perfusion CT measurement of regional cerebral blood flow. AJNR Am J Neuroradiol 2000;21:1881-1884.
7. Patlak CS, Balsberg RG, Fernstmacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983;3:1-7.
8. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
9. Bland JM, Altman DG. Applying the right statistics: analyses of measurement studies. Ultrasound Obstet Gynecol 2003;22:85-93.
10. World Health Organization. WHO hand book for reporting results of cancer treatment. WHO offset publication no. 48. Geneva, Switzerland: World Health Organization, 1979.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92: 205-216.
12. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
13. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY. Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 2000;7:840-850.
14. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 2004;233:191-199.
15. Tateishi U, Nishihara H, Tsukamoto E, Morikawa T, Tamaki N, Miyasaka K. Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism. J Comput Assist Tomogr 2002;26:185-190.
16. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br J Cancer 1995;71:1210-1213.
17. Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia find reoxygenation in tumor parenchyma. Cancer Res 1996;56:5522-5528.
18. Miles KA, Griffiths MR, Fuentes MA. Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG-PET in lung nodules. Radiology 2001;220:548-553.
19. Miles KA, Kelley BB. CT measurements of capillary permeability within nodal masses: a potential technique for assessing the activity of lymphoma. Br J Radiol 1997;70:74-79.
20. Miles KA, Leggett DA, Bennett GA. CT derived Patlak images of the human kidney. Br J Radiol 1999;72:153-158.
21. Nabavi DG, Cenic A, Dool J, et al. Quantitative assessment of cerebral hemodynamics using CT: stability, accuracy, and precision studies in dogs. J Comput Assist Tomogr 1999;23:500-515.
22. Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. A CT method to measure hemodynamics in brain tumors: validation and application of cerebral blood flow maps. AJNR Am J Neuroradiol 2000;21:462-470.
23. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft tissue tumour. Phys Med Biol 2001;46:3161-3175.
24. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumors: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-142.
25. Ng QS, Goh V, Hoskin PJ, Carnell D, Meer K, Padhani A. Tumor antivascular effects of combretastatin A4 phosphate (CA4P) in combination with radiotherapy measured using dynamic contrast enhanced computed tomography (DCE-CT) (abstract). Radiother Oncol 2004;73(suppl 1): 322.
26. Fiorella D, Heiserman J, Prenger E, Pavtovi S. Assessment of the reproducibility of postprocessing dynamic CT perfusion data. AJNR Am J Neuroradiol 2004;25:97-107.
27. Goh V, Halligan S, Hugill JA, Bassett P, Bartram CI. Quantitative assessment of colorectal perfusion using MDCT: inter- and intra observer agreement. AJR Am J Roentgenol 2005;185:225-231.